Chemistry:Ziresovir
From HandWiki
Short description: Medication
Clinical data | |
---|---|
Trade names | Ziresovir |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C22H25N5O3S |
Molar mass | 439.53 g·mol−1 |
3D model (JSmol) | |
| |
|
Ziresovir (RO-0529, AK0529) is an antiviral drug which was developed as a treatment for respiratory syncytial virus. It acts as a fusion inhibitor, and has shown good results in Phase II and III clinical trials.[1][2][3]
See also
- Palivizumab
- Presatovir
- Lumicitabine
References
- ↑ "Discovery of Ziresovir as a Potent, Selective, and Orally Bioavailable Respiratory Syncytial Virus Fusion Protein Inhibitor". Journal of Medicinal Chemistry 62 (13): 6003–6014. July 2019. doi:10.1021/acs.jmedchem.9b00654. PMID 31194544.
- ↑ "Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference". Antiviral Research 167: 45–67. July 2019. doi:10.1016/j.antiviral.2019.04.006. PMID 30974127.
- ↑ Taylor, Nick Paul (7 April 2022). "ArkBio's ex-Roche antiviral hits primary goal in RSV phase 3, sparking race to regulator and wait for more data" (in en). https://www.fiercebiotech.com/biotech/arkbios-ex-roche-antiviral-hits-primary-goal-rsv-phase-3-sparking-race-regulator-and-wait.
Original source: https://en.wikipedia.org/wiki/Ziresovir.
Read more |